CD274 and breast carcinoma: A systemic review and meta-analysis of 2546 breast cancer patients showed a PD-L1 positive rate of 21%−56%, and PD-L1 expression was suggested as a promising biomarker for selecting patients who may benefit from immunotherapy31.